	 World Health Organization Senior management heard a spectrum of comments from stakeholders, ranging from Pfizer being seen as an inflexible business partner, to questions about the stock price and from awe at Pfizer’s scientists for their skills and dedication, to surprise at the scope of our partnerships in improving access to medicines.